Who Is Buying Dental Practices in 2026?

Roughly 130 private-equity-backed DSOs are actively acquiring dental practices in 2026, and 61% of surveyed DSOs report that their private equity backers expect a moderate or high increase in acquisition activity this year. The Association of Dental Support Organizations counts more than 80 member companies supporting over 8,500 practices. That is the buyer universe in one paragraph: consolidated, well-capitalized and still hungry.

But “a DSO bought it” describes four genuinely different transactions. Knowing which category is circling your practice tells you more about your eventual number than any multiple table will.

At a Glance

  • Active PE-backed DSOs: roughly 130
  • ADSO membership: 80+ companies supporting 8,500+ practices
  • Single-location DSO pricing: 5.0x-8.0x EBITDA
  • Multi-location, $1M+ EBITDA: 8.0x-11.0x EBITDA
  • Platform-grade, $5M+ EBITDA: 10.0x-12.0x EBITDA
  • Add-on tuck-ins: 4.0x-7.0x EBITDA
  • Private/associate buyers: 60%-85% of trailing-twelve-month collections
  • Sponsor outlook: 61% of DSOs expect acquisition volume to rise in 2026

Who are the biggest dental practice buyers in 2026?

Four categories, in descending order of deal volume. The national DSO platforms come first — Heartland Dental, Aspen Dental, Pacific Dental Services and Smile Brands. These are the acquirers with the deepest capital and the most rigid integration models, and they typically want your practice on their software, their supply contracts and their compensation structure on day one. Second, the doctor-partnership and joint-venture models, principally MB2 Dental and Imagen Dental Partners, which buy a majority stake and leave the selling dentist with meaningful rolled equity and clinical autonomy. Third, the regional consolidators: North American Dental Group, Mortenson Dental Partners and Dental Care Alliance, which tend to pay competitively inside their existing footprint and less well outside it. Fourth, a long tail of emerging PE-backed platforms assembling their first five to fifteen locations. That last group is where the surprises come from — a sponsor building a platform will occasionally pay above the range for a practice that anchors a new market, because their alternative is starting from scratch.

What are DSOs actually paying?

DSOs generally pay 5.0x to 8.0x adjusted EBITDA for a single-location general practice, and 8.0x to 11.0x for multi-location groups with $1 million or more of EBITDA. Practices under $1 million of EBITDA clear 5.0x to 7.0x as small tuck-ins; $1 million to $3 million lands at 7.0x to 9.0x as regional add-ons; $3 million to $5 million reaches 9.0x to 11.0x in emerging-platform deals; and above $5 million you are in platform territory at 10.0x to 12.0x. Pure add-on acquisitions bolting onto existing infrastructure price lower, at 4.0x to 7.0x, because the buyer is acquiring chair capacity rather than a business. Headline multiples have held steady for two consecutive years after moderating from the 2021 to 2023 peak. What has changed is selectivity: the gap between the best offer and the middle offer on the same practice has widened, which is precisely why running a process beats answering a letter. My full dental valuation walkthrough covers how buyers rebuild your earnings before applying any of these multiples.

Are private equity firms still backing DSOs in 2026?

Yes, and the survey data is the clearest signal available: 61% of DSOs report their sponsors expect moderate or high increases in acquisition activity in 2026. The structural logic has not changed. Dentistry remains highly fragmented, largely recession-resistant, and generates the recurring hygiene revenue that sponsors underwrite comfortably. What has changed is discipline. Sponsors that overpaid in 2021 and 2022 are now underwriting to defensible adjusted EBITDA rather than adjusted-adjusted EBITDA, and diligence on payer mix, hygiene production and associate retention is materially tougher than it was three years ago. Practices that cannot survive that scrutiny are not getting the headline numbers they read about.

Should I sell to a DSO or a private buyer?

It depends on what you are optimizing for, and the honest answer is that most dentists optimize for the wrong variable. A DSO will almost always beat a private buyer on headline price for a practice above roughly $1 million in collections, but a meaningful share of that price arrives as rolled equity and an employment agreement with production targets attached. A private or associate buyer pays less — typically 60% to 85% of trailing collections — but pays it cleanly and lets you walk. If you are five years from retirement and want a second bite when the platform recapitalizes, the DSO route is genuinely attractive. If you want to be finished in eighteen months, the cleanest DSO deal still has you working. The dental practice valuation page lays out the readiness checklist for both paths.

John’s Take

I had a two-location general practice at $3.4 million in collections and about $760,000 of adjusted EBITDA. The owner had a letter from a national platform at 6.8x and assumed that was the market. We ran seven parties. The winning bid came from an emerging platform buying its ninth location at 9.1x, because that practice anchored a market they had been trying to enter for two years. Same practice, same financials, 2.3 turns of difference — roughly $1.7 million — determined entirely by which buyer needed it most. The letter in your mailbox is never the market. It is one buyer’s opening position.

Find Out What Your Dental Practice Business Is Worth

Start with the free valuation calculator to get a defensible range in a few minutes. When you want to know which category of buyer would compete hardest for your practice — and what they would adjust in your earnings — we can talk confidentially. Nothing goes to market without your sign-off.

Schedule a Confidential Consultation

Frequently Asked Questions

Who are the biggest dental practice buyers in 2026?
Four categories account for essentially all institutional deal volume. The national DSO platforms lead: Heartland Dental, Aspen Dental, Pacific Dental Services and Smile Brands. They carry the deepest capital and the most rigid integration models, and they generally want your practice converted to their software, supply contracts and compensation structure quickly after closing. Second are the doctor-partnership and joint-venture models, principally MB2 Dental and Imagen Dental Partners, which acquire a majority stake while leaving the selling dentist with meaningful rolled equity and real clinical autonomy. Third are the regional consolidators, including North American Dental Group, Mortenson Dental Partners and Dental Care Alliance, which tend to pay competitively inside their existing footprint and noticeably less well outside it. Fourth is a long tail of emerging private-equity-backed platforms assembling their first five to fifteen locations, and this is where the pricing surprises come from. A sponsor building a platform will occasionally pay well above the standard range for a practice that anchors a market they want, because their alternative is building from scratch. Roughly 130 PE-backed DSOs are active overall, and ADSO counts 80-plus member companies supporting more than 8,500 practices.
What are DSOs actually paying for dental practices in 2026?
DSOs generally pay 5.0x to 8.0x adjusted EBITDA for a single-location general practice and 8.0x to 11.0x for multi-location groups with $1 million or more of EBITDA. Broken down more finely: practices under $1 million of EBITDA clear 5.0x to 7.0x as small tuck-ins; $1 million to $3 million of EBITDA lands at 7.0x to 9.0x as regional add-ons; $3 million to $5 million reaches 9.0x to 11.0x in emerging-platform transactions; and above $5 million of EBITDA you are in genuine platform territory at 10.0x to 12.0x. Pure add-on acquisitions that bolt onto existing infrastructure price lower, at 4.0x to 7.0x, because the buyer is acquiring chair capacity rather than a standalone business. Headline multiples have now held steady for two consecutive years after moderating from the 2021 to 2023 peak. The meaningful change is selectivity rather than level: the spread between the best offer and the middle offer on the same practice has widened substantially, which is exactly why running a competitive process produces a different outcome than responding to a single unsolicited letter.
Are private equity firms still backing dental DSOs in 2026?
Yes. The clearest available signal is that 61% of surveyed DSOs report their private equity backers expect a moderate or high increase in acquisition activity in 2026. The structural thesis has not changed: dentistry remains highly fragmented, is largely recession-resistant because people do not stop needing hygiene visits, and generates the recurring revenue base that sponsors underwrite comfortably. Roughly 130 PE-backed DSOs are competing for practices right now. What has changed is discipline. Sponsors who overpaid during the 2021 and 2022 peak are now underwriting to defensible, normalized adjusted EBITDA rather than accepting aggressive add-backs, and diligence on payer mix, hygiene production per operatory, associate retention and doctor dependence is materially tougher than it was three years ago. The practical consequence for a seller is that the headline multiples you read about are real but conditional. A practice that cannot survive that scrutiny will see its adjusted EBITDA marked down in diligence, and a lower multiple applied to a lower number compounds against you quickly.
Should I sell my dental practice to a DSO or a private buyer?
It depends on what you are optimizing for, and most dentists optimize for the wrong variable. A DSO will almost always beat a private buyer on headline price for a practice above roughly $1 million in collections, but a meaningful portion of that price typically arrives as rolled equity plus an employment agreement with production targets attached. You are trading certainty for upside and continued work. A private or associate buyer pays less, typically 60% to 85% of trailing-twelve-month collections, but pays it cleanly and lets you exit on a defined timeline. If you are five or more years from retirement and want a second bite when the platform recapitalizes, the DSO path is genuinely attractive and the equity can be worth more than the cash at closing. If you want to be finished within eighteen months, understand that even the cleanest DSO transaction still has you practicing, and that a transition agreement you resent is worth less than the dollars it carries. Private buyers also remain the majority of transactions under roughly $1 million in collections simply because institutional buyers cannot clear their diligence costs at that size.